These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 12821935)

  • 1. Estrogen receptor-alpha regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells.
    Morelli C; Garofalo C; Bartucci M; Surmacz E
    Oncogene; 2003 Jun; 22(26):4007-16. PubMed ID: 12821935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear insulin receptor substrate 1 interacts with estrogen receptor alpha at ERE promoters.
    Morelli C; Garofalo C; Sisci D; del Rincon S; Cascio S; Tu X; Vecchione A; Sauter ER; Miller WH; Surmacz E
    Oncogene; 2004 Sep; 23(45):7517-26. PubMed ID: 15318176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IRS-1 expression and activation are not sufficient to activate downstream pathways and enable IGF-I growth response in estrogen receptor negative breast cancer cells.
    Jackson JG; Yee D
    Growth Horm IGF Res; 1999 Oct; 9(5):280-9. PubMed ID: 10543935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth.
    Oesterreich S; Zhang P; Guler RL; Sun X; Curran EM; Welshons WV; Osborne CK; Lee AV
    Cancer Res; 2001 Aug; 61(15):5771-7. PubMed ID: 11479214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of IRS-1 signaling in insulin-induced modulation of estrogen receptors in breast cancer cells.
    Andò S; Panno ML; Salerno M; Sisci D; Mauro L; Lanzino M; Surmacz E
    Biochem Biophys Res Commun; 1998 Dec; 253(2):315-9. PubMed ID: 9878535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2.
    Cui X; Lazard Z; Zhang P; Hopp TA; Lee AV
    Oncogene; 2003 Oct; 22(44):6937-41. PubMed ID: 14534541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinoic acid mediates degradation of IRS-1 by the ubiquitin-proteasome pathway, via a PKC-dependant mechanism.
    del Rincón SV; Guo Q; Morelli C; Shiu HY; Surmacz E; Miller WH
    Oncogene; 2004 Dec; 23(57):9269-79. PubMed ID: 15516986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines.
    Jackson JG; Zhang X; Yoneda T; Yee D
    Oncogene; 2001 Nov; 20(50):7318-25. PubMed ID: 11704861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNAi-mediated silencing of insulin receptor substrate 1 (IRS-1) enhances tamoxifen-induced cell death in MCF-7 breast cancer cells.
    Cesarone G; Garofalo C; Abrams MT; Igoucheva O; Alexeev V; Yoon K; Surmacz E; Wickstrom E
    J Cell Biochem; 2006 May; 98(2):440-50. PubMed ID: 16440325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer.
    Surmacz E; Bartucci M
    J Exp Clin Cancer Res; 2004 Sep; 23(3):385-94. PubMed ID: 15595626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor alpha and beta subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells.
    Gougelet A; Bouclier C; Marsaud V; Maillard S; Mueller SO; Korach KS; Renoir JM
    J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):71-81. PubMed ID: 15862952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration.
    Cui X; Kim HJ; Kuiatse I; Kim H; Brown PH; Lee AV
    Cancer Res; 2006 May; 66(10):5304-13. PubMed ID: 16707456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Up-regulation of PI3K/Akt signaling by 17beta-estradiol through activation of estrogen receptor-alpha, but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells.
    Lee YR; Park J; Yu HN; Kim JS; Youn HJ; Jung SH
    Biochem Biophys Res Commun; 2005 Nov; 336(4):1221-6. PubMed ID: 16169518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin receptor substrate 1 modulates the transcriptional activity and the stability of androgen receptor in breast cancer cells.
    Lanzino M; Garofalo C; Morelli C; Le Pera M; Casaburi I; McPhaul MJ; Surmacz E; Andò S; Sisci D
    Breast Cancer Res Treat; 2009 May; 115(2):297-306. PubMed ID: 18521741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estradiol increases IRS-1 gene expression and insulin signaling in breast cancer cells.
    Mauro L; Salerno M; Panno ML; Bellizzi D; Sisci D; Miglietta A; Surmacz E; Andò S
    Biochem Biophys Res Commun; 2001 Nov; 288(3):685-9. PubMed ID: 11676497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells.
    Balasenthil S; Barnes CJ; Rayala SK; Kumar R
    FEBS Lett; 2004 Jun; 567(2-3):243-7. PubMed ID: 15178330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Angiogenic effect of interleukin-8 in breast cancer and its association with estrogen receptor].
    Lin Y; Wang SM; Huang RP
    Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(20):1419-23. PubMed ID: 16029657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation.
    Journe F; Laurent G; Chaboteaux C; Nonclercq D; Durbecq V; Larsimont D; Body JJ
    Breast Cancer Res Treat; 2008 Jan; 107(1):49-61. PubMed ID: 17333335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V; Gougelet A; Maillard S; Renoir JM
    Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.